Previous studies have specifically examined the preclinical efficacy of LSD1, HDAC, EZH2, and BET inhibitors on MCC cell lines and mouse studies to understand whether these agents hold the potential for clinical translation. This evidence concerns the gene KDM1A and Merkel cell skin cancer.